- Process for preparing azelaic acid
-
A process for preparing azelaic acid is disclosed. In particular, the process for preparing azelaic acid is an ozone free process. The process for preparing azelaic acid comprises a step of decarboxylation of tetra-carboxylic acid in the presence of a organic sulfonic acid.
- -
-
Paragraph 0090; 0091
(2021/02/19)
-
- BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME
-
Described herein are compounds capable of modulating one or more biomolecules substantially simultaneously, e.g., modulating two or more binding domains (e.g., bromodomains) on a protein or on different proteins. For example, in one aspect, a bivalent compound or a pharmaceutically acceptable salt, stereoisomer, metabolite, or hydrate thereof is provided. In another aspect, a method of treating a disease associated with a protein having tandem bromodomains in a patient in need thereof is provided. The method comprises administering to the patient the bivalent compound as described.
- -
-
Paragraph 00357-00361; 00376; 00377
(2015/06/11)
-
- Toward analogues of MraY natural inhibitors: Synthesis of 5′-triazole-substituted-aminoribosyl uridines through a Cu-catalyzed azide-alkyne cycloaddition
-
A straightforward strategy for the synthesis of triazole-containing MraY inhibitors has been developed. It involves the sequential introduction of a terminal alkyne at the 5′ position of an uridine derivative and O-glycosylation with a protected aminoribose leading to an elaborated alkyne scaffold. An efficient Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) allowed the introduction of chemical diversity toward a small library of inhibitors.
- Fer, Mickael J.,Olatunji, Samir,Bouhss, Ahmed,Calvet-Vitale, Sandrine,Gravier-Pelletier, Christine
-
p. 10088 - 10105
(2013/11/06)
-
- Rationally-designed S-chiral bissulfinamides as highly enantioselective organocatalysts for reduction of ketimines
-
We recently reported the first example of S-chiral organocatalysts, that are highly efficient and enantioselective in substoichometric amounts, and which use a chiral monosulfinamide group as Lewis base to activate trichlorosilane (HSiCl3) to reduce N-arylketimines. Aplausible mechanism involving two molecules of the monosulfinamde catalyst for the activation of HSiCl 3 prompted us to design S-chiral bissulfinamides as new catalysts. We herein describe our findings that an easily prepared S-chiral bissulfinamide bearing a five-methylene linkage not only inherited the excellent substrate generality from the monosulfinamide catalysts, but also exhibited further improved enantioselectivity.
- Pei, Dong,Zhang, Yu,Wei, Siyu,Wang, Meng,Sun, Jian
-
supporting information; experimental part
p. 619 - 623
(2009/04/21)
-
- Determination of busulfan in plasma by GC-MS with selected-ion monitoring
-
A GC-MS technique with selected-ion monitoring is described for the determination of busulfan in plasma. Busulfan is extracted from plasma with methylene chloride and converted to 1,4-diiodobutane. Analysis by GC-MS with selected-ion monitoring (m/z 183) gave a relative standard deviation of ± 4.3% (n = 5) at the 10-ng/ml level.
- Ehrsson,Hassan
-
p. 1203 - 1205
(2007/10/02)
-